Recent studies show that a series of AD risk gene mutations are associated with immune responses and endocytosis, and these include ATP-binding cassette transporter A7, CD33, triggering receptor expressed on myeloid cells-2 (TREM2) and complement receptor 1. The gene discussed is CD33; the disease is Alzheimer disease.